From the Guidelines
Jublia (efinaconazole) is the most effective topical treatment for onychomycosis, with mycological cure rates approaching 50% and complete cure in 15% of patients after 48 weeks of application. According to the British Association of Dermatologists' guidelines for the management of onychomycosis 2014 1, once-daily application of topical 10% efinaconazole has been found to be more effective than vehicle in the treatment of onychomycosis. The standard regimen involves applying the solution once daily to the affected nail(s) using the brush applicator, continuing treatment for 48 weeks.
- Key points to consider when using Jublia include:
- Apply to clean, dry nails, allowing the solution to fully dry before wearing socks or shoes
- Common side effects may include mild irritation at the application site
- Patients should continue the full treatment course even if improvement is seen early, as nail fungus requires persistent therapy for complete eradication
- Visible improvement typically begins after several weeks of consistent use, with full nail clearing potentially taking months as the healthy nail grows out Other topical treatments, such as terbinafine, butenafine, bifonazole, salicylic acid, and urea ointment, have limited data to support their use as monotherapy for onychomycosis, making Jublia the preferred choice 1.
From the FDA Drug Label
1 INDICATIONS AND USAGE JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
The main use of Jublia is for the topical treatment of onychomycosis of the toenail(s) caused by Trichophyton rubrum and Trichophyton mentagrophytes 2.
- Key points:
- Indication: onychomycosis of the toenail(s)
- Causative pathogens: Trichophyton rubrum and Trichophyton mentagrophytes
- Treatment type: topical treatment
- Drug class: azole antifungal
From the Research
Overview of Jublia (Efinaconazole 10% Solution)
- Jublia, also known as efinaconazole 10% solution, is a topical antifungal treatment for onychomycosis, a fungal nail infection 3, 4, 5, 6, 7.
- It is approved by the FDA for the treatment of onychomycosis in adult and pediatric patients aged 6 years and older 3, 7.
Efficacy of Jublia
- Studies have shown that efinaconazole 10% solution is effective in treating onychomycosis, with mycological cure rates ranging from 53.4% to 65% and complete cure rates ranging from 15.2% to 40% 4, 5, 6, 7.
- Efinaconazole has been shown to be safe and efficacious regardless of disease severity, duration, patient gender, ethnicity, or age, including pediatrics 5.
- It has comparable efficacy to systemic antifungal agents such as itraconazole, and a favorable adverse events profile with minimal systemic exposure and no drug-drug interactions 5, 6.
Safety and Tolerability of Jublia
- Efinaconazole 10% solution has been found to be safe and well-tolerated in both adult and pediatric populations, with minimal localized adverse events such as ingrown toenails, dermatitis, vesicles, and pain at the application site 3, 4, 6, 7.
- The most common adverse events associated with efinaconazole were local site reactions, which ceased upon stopping treatment 4, 6.
Use of Jublia in Pediatric Onychomycosis
- Efinaconazole 10% solution is approved by the FDA for the treatment of pediatric onychomycosis in children aged 6 years and older 7.
- A phase-IV, multicenter, open-label study found that efinaconazole solution 10% was safe and well-tolerated in children aged 6-16 years with culture-positive, mild-to-severe distal and lateral subungual onychomycosis 7.
- By week 52, the mycological cure was 65%, and the complete cure was 40% in this pediatric population 7.